Cadila Healthcare is currently trading at Rs. 443.15, up by 7.05 points or 1.62% from its previous closing of Rs. 436.10 on the BSE.
The scrip opened at Rs. 438.00 and has touched a high and low of Rs. 450.55 and Rs. 433.40 respectively. So far 85,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 558.00 on 12-Jun-2017 and a 52 week low of Rs. 334.35 on 31-Jan-2017.
Last one week high and low of the scrip stood at Rs. 450.95 and Rs. 426.40 respectively. The current market cap of the company is Rs. 45,367.00 crore.
The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 16.93% and 8.28% respectively.
The US Food and Drug Administration (USFDA) has completed an inspection at Cadila Healthcare’s API manufacturing facility at Dabhasa. The facility was inspected in the period from January 15, 2018 to January 19, 2018. At the end of the inspection, no observation (483) was issued.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1483.75 |
Dr. Reddys Lab | 5947.30 |
Cipla | 1347.70 |
Zydus Lifesciences | 958.90 |
Lupin | 1580.00 |
View more.. |